Pioglitazone Treatment Improves Nitrosative Stress in Type 2 Diabetes

Vinik, Aaron I.; Ullal, Jagdeesh; Parson, Henri K.; Barlow, Patricia M.; Casellini, Carolina M.
April 2006
Diabetes Care;Apr2006, Vol. 29 Issue 4, p869
Academic Journal
OBJECTIVE -- The purpose of this study was to determine the effect of 24 weeks of treatment with 45 mg/day pioglitazone on peripheral skin blood flow (SkBF) and skin nitric oxide (NO) production in vivo in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS -- This was a randomized, parallel, cross-over, double-blind, within- and between-subject study designed to compare vascular responses before and after treatment. We studied 12 subjects with type 2 diabetes (average age 58.6 ± 30.8 years, HbA[sub 1c] 7.9 ± 00.4%, BM 131.3 ± 1.2 kg/m²). SkBF was measured using laser Doppler techniques in response to ischemia reperfusion and local skin warming, and NO production was assessed in vivo using an amperometric NO meter inserted directly into the skin. These measurements were performed before treatment and at 6 and 24 weeks. RESULTS -- The SkBF response was not significantly improved after 24 weeks in either of the groups. NO production was significantly decreased in the pioglitazone-treated group in the basal condition (area under the curve 6.4 ± 1.0 vs. 2.8 ± 0.8, P < 0.01), after local heat stimulation at 40°C (12.9 ± 2.2 vs. 5.7 ± 1.7, P < 0.01), and after nociceptor stimulated flow with local heating at 44°C (36.4 ± 6.3 vs. 16.6 ± 3.4). Differences were not significant in the placebo-treated group. CONCLUSIONS -- Treatment of patients with type 2 diabetes with pioglitazone for 24 weeks reduced skin NO production, thus probably reducing nitrosative stress without a demonstrable effect on SkBF. Because nitrosative stress is considered to be a factor in the pathogenesis of neurovascular dysfunction, these findings warrant further investigation.


Related Articles

  • Exercise Status Is an Important Determinant of the Microvascular Effects of L-NAME and Aspirin on Dorsal Foot Skin Perfusion in Type 2 Diabetes. Colberg, Sheri R.; Parson, Henri K.; Azoury, Krystel R.; Jones, Erikca C.; Vinik, Aaron I. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA280 

    A profound defect in dorsal foot skin perfusion in response to heating in type 2 diabetic individuals has been observed. In prior studies, we have determined that most of this defect correlates with insulin resistance, may be related to the integrity of small unmyelinated C-fiber nerves, is...

  • DIAD: Outcome not affected by routine screening for CAD in patients with diabetes. Haigh, Christen; Kalvaitis, Katie; Raible, Eric; Southall, Jennifer // Endocrine Today;May2009, Vol. 7 Issue 7, p16 

    The article reports on a study presented at a press briefing held by the "Journal of the American Medical Association" in Washington, D. C. which showed that screening patients with type 2 diabetes for inducible ischemia was not able to identify patients who were at greater risk than others.

  • Pulsed infrared light therapy does not increase nitric oxide concentration in the blood of patients with type 1 and type 2 diabetes mellitus. Arnall, David Alan; Nelson, Arnold G.; Stambaugh, Laura; Sevilla, Núria Sanz; i Iranzo, M. Àngels Cebrià; Bueno, Laura López; Sanz, Isabel; Arnall, Sheridan B. // Acta Diabetologica;Sep2009, Vol. 46 Issue 3, p233 

    The purpose of this study was to determine if NO blood concentrations increased acutely following an 8-week course of pulsed infrared light therapy (PILT) which could be linked to an improvement in peripheral protective sensation (PPS) in patients who have profound chronic diabetic peripheral...

  • Peroxidaci�n Lip�dica y Nitritos Plasm�ticos en Pacientes Diab�ticos Tipo 2. Estudio Preliminar. Carrizales, Maira; Torres, Marisabel; Sutil, Rosalia; Mu�oz, Marielena; G�mez, Maria Esther // Informe Medico;may2007, Vol. 9 Issue 5, p227 

    The increase of lipidic peroxidation and decrease in nitric oxide (NO) levels has been associated to polyneuropathy and to macro and micro vascular complications observed in diabetes mellitus. Objective: to determine seric levels of lipidic peroxidation and nitrates concentration in type 2...

  • A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. Wen QIN; Rong ZHANG; Cheng HU; Cong-rong WANG; Jing-yi LU; Wei-hui YU; Yu-qian BAO; Kun-san XIANG; Wei-ping JIA // Acta Pharmacologica Sinica;Apr2010, Vol. 31 Issue 4, p450 

    AbstractAim:To investigate a potential association between SNP rs10494366 in the neural nitric oxide synthase adaptor protein (NOS1AP) and efficacy of repaglinide (an insulin secretagogue) in newly diagnosed Shanghai Chinese type 2 diabetes patients.Methods:A total of 104 newly diagnosed type 2...

  • Insulin reduced plasma arginase activity in patients with type 2 diabetes.  // Endocrine Today;2/25/2008, Vol. 6 Issue 3, p20 

    The article discusses the findings of a study regarding plasma arginase activity in relation to type 2 diabetes. The study was done to 12 patients with type 2 diabetes and 10 people without diabetes before and after euglycemic-hyperinsulinemic clamp with muscle biopsies for four hours wherein...

  • L-Arginine Supplementation in Type II Diabetic Rats Preserves Renal Function and Improves Insulin Sensitivity by Altering the Nitric Oxide Pathway. Claybaugh, Taylor; Decker, Sarah; McCall, Kelly; Slyvka, Yuriy; Steimle, Jerrod; Wood, Aaron; Schaefer, Megan; Thuma, Jean; Inman, Sharon // International Journal of Endocrinology;2014, p1 

    Rat studies demonstrated that type II diabetes mellitus (T2DM) decreases both the production and bioavailability of nitric oxide (NO). L-arginine (LA) provides the precursor for the production of NO. We hypothesized that LA dietary supplementation will preserve NO production via endothelial...

  • L-Arginine--Nitric Oxide Kinetics in Normal and Type 2 Diabetic Subjects. Avogaro, Angelo; Toffolo, Gianna; Kiwanuka, Edward; de Kreutzenberg, Saula Vigili; Tessari, Paolo; Cobelli, Claudio // Diabetes;Mar2003, Vol. 52 Issue 3, p795 

    Defective endothelium is a key event in the development of atherosclerosis in diabetes: alteration of the L-arginine-nitric oxide (NO) pathway has been suggested. We propose a modeling approach of the L-arginine-NO pathway in vivo in both control and type 2 diabetic subjects based on the...

  • Liraglutide: Promise of the Incretin Class.  // Clinical Cardiology Alert;Mar2009 Clinical Briefs, p5 

    The article discusses research being done on liraglutide. It references a study by M. Nauck et al, published in a 2009 issue of "Diabetes Care." To examine the effect of liraglutide on diabetics, researchers performed a double-blind, controlled trial of the hormone against glimepiride or placebo...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics